Q-omics provides the consensus-scored STARD13-IT1 profile across patient tissues and cancer cell-line models. STARD13-IT1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, STARD13-IT1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, STARD13-IT1 RNA expression shows 10,954 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, THCA, and LSCC as cancer lineages where STARD13-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STARD13-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STARD13-IT1 survival associations across molecular data types. STARD13-IT1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STARD13-IT1 RNA expression–survival associations across cancer types. High STARD13-IT1 expression shows unfavorable associations in CESC, KIRP and MESO, but favorable associations in UCS, OV and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify CESC as the clearest survival context for STARD13-IT1 RNA expression.
This table summarizes STARD13-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for STARD13-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STARD13-IT1 shows lower tumor expression in THCA, KIRC, KICH, KIRP and READ and higher tumor expression in PAAD. The THCA box plot shows higher STARD13-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.328, t-test p < 0.001).
This table shows molecular features associated with STARD13-IT1 in patient tissues and cancer cell lines. In patient samples, STARD13-IT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
